文献速递胸部CT

可切除肺腺癌患者的结局预测:CT影像组学的价值

Outcome prediction in resectable lung adenocarcinoma patients: value of CT radiomics.
PubMed 文献 · Eur Radiol · 2020-04-30

该回顾性分析纳入1058例接受治愈性手术的肺腺癌患者(训练队列754例,时间验证队列304例),从术前增强CT提取影像组学特征构建预测无病生存期和总生存期的影像组学标签。影像组学标签是无病生存期(HR 1.920,p<0.001)和总生存期(HR 2.079,p<0.001)的独立预后因素,加入临床病理模型可提高无病生存期预测的C指数(训练队列0.764 vs 0.713,p<0.001;验证队列0.782 vs 0.734,p=0.016),但对总生存期的改善在验证队列未达统计学显著(0.805 vs 0.734,p=0.149)。

要点

  • CT影像组学标签可独立预测可切除肺腺癌的无病生存期和总生存期。
  • 影像组学联合分期和病理亚型可提高无病生存期预测的C指数。
  • 联合模型可将患者分为高、中、低风险组。

核心结论

  • CT影像组学可有效预测肺腺癌患者预后,提供超越临床病理风险因素的额外预后信息。

研究设计与样本

  • 回顾性分析纳入1058例接受治愈性手术的肺腺癌患者,训练队列754例,时间验证队列304例。
  • 从术前增强CT提取影像组学特征,构建预测无病生存期和总生存期的影像组学标签。
  • 采用单变量和多变量Cox比例风险回归分析评估影像组学标签与预后的关联。
  • 使用一致性指数(C-index)评估影像组学标签超越临床病理风险因素的增量价值。

诊断标准与关键数值

  • 影像组学标签独立预测无病生存期(HR 1.920,p<0.001)和总生存期(HR 2.079,p<0.001)。
  • 影像组学标签预测无病生存期的C指数为0.724,分期为0.685;预测总生存期的C指数为0.735,分期为0.703。
  • 影像组学联合分期和病理亚型预测无病生存期,训练队列C指数0.764 vs 0.713(p<0.001),验证队列0.782 vs 0.734(p=0.016)。
  • 影像组学联合分期和年龄预测总生存期,训练队列C指数0.784 vs 0.737(p<0.001),验证队列0.805 vs 0.734(p=0.149)。

临床应用与阅片要点

  • 本研究结论提示CT影像组学标签可能为可切除肺腺癌提供额外预后信息,但原文未据此给出具体临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: Lung adenocarcinoma shows broad spectrum of prognosis and histologic heterogeneity. This study was to investigate the prognostic value of CT radiomics in resectable lung adenocarcinoma patients and assess its incremental value over clinical-pathologic risk factors.

METHODS: This retrospective analysis evaluated 1058 patients who underwent curative surgery for lung adenocarcinoma (training cohort: N = 754; temporal validation cohort: N = 304). Radiomics features were extracted from preoperative contrast-enhanced CT. Radiomics signature to predict disease-free survival (DFS) and overall survival (OS) was generated. Association between the radiomics signature and prognosis were evaluated using univariable and multivariable Cox proportional hazards regression analyses. Incremental value of the radiomics signature beyond clinical-pathologic risk factors was assessed using concordance index (C-index).

RESULTS: The radiomics signatures were independently associated with DFS (hazard ratio [HR], 1.920; p < 0.001) and OS (HR, 2.079; p < 0.001). The radiomics signature showed performance comparable to stage in estimation of DFS (C-index, 0.724 vs 0.685) and OS (0.735 vs 0.703). The radiomics added prognostic value to clinical-pathologic models (stage and histologic subtype) in predicting DFS (C-index, 0.764 vs 0.713; p < 0.001), which was also shown in the validation cohort (0.782 vs 0.734; p = 0.016). In terms of OS, including radiomics led to significant improvement in prognostic performance of the clinical-pathologic model (stage and age) in the training cohort (0.784 vs 0.737; p < 0.001), but the improvement was not significant in the validation cohort (0.805 vs 0.734; p = 0.149).

CONCLUSIONS: CT radiomics was effective in predicting prognosis in lung adenocarcinoma patients, providing additional prognostic information beyond clinical-pathologic risk factors.

KEY POINTS: • CT radiomics signature was an independent prognostic factor predicting disease-free and overall survival along with clinical risk factors of lung adenocarcinoma (stage, histologic subtype, and age). • CT radiomics added prognostic value to clinical-pathologic models (stage and subtype) in predicting disease-free survival (C-index for integrated model and clinical-pathologic model, 0.764 vs 0.713; p < 0.001), which was also proven in the validation cohort (0.782 vs 0.734; p = 0.016). • Integrated model incorporating radiomics signature can successfully stratify patients into high-risk, intermediate-, or low-risk groups in patients with resectable lung adenocarcinoma.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Choe J, Lee SM, Do KH, et al. Outcome prediction in resectable lung adenocarcinoma patients: value of CT radiomics. Eur Radiol. 2020. PMID: 32356158. doi:10.1007/s00330-020-06872-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。